 |
| Medolac/MMC says this commercially sterile human milk product has a 3 year shelf life. |
Medolac/MMC continues to promote the product for sale. They continue to make reference to it being used currently in hospitals in the US. Pricing information remains unclear and I've been unable to confirm with anyone, anywhere, what hospital might be using the product.
The most product recent sales pitch at the end of 2014 was a "Buy Three Cases Get Two Free" offer. The last price offered after that deal was calculated looks to be around $6/oz. However MMC's CEO Adrienne Weir said in early January 2015 the price for the product is $4/oz. Further, she has reiterated that there are "hospital partners," NICUS in the US that are using the product.
Has any hospital purchased this milk? Or has anyone heard of anyone that has purchased this milk? Is any hospital using this milk after receiving it as a donation, free of charge, or on an experimental basis?
If you have any information, I can be reached privately by email. You can also make a completely anonymous comment on this blog - and if you don't want even your anonymous comment made public, let me know and I will not publish it.
If you have any information, I can be reached privately by email. You can also make a completely anonymous comment on this blog - and if you don't want even your anonymous comment made public, let me know and I will not publish it.
Jodine Chase
Human Milk News
3 comments:
I believe in Louisville, Kentucky they are using it in their NICU.
Interesting. Valerie McClain came by my Facebook page and dropped off this report of a research study out of the University of Louisville:
"Donor Human Milk for Infants With Neonatal Abstinence Syndrome"
Donor Human Milk in Neonatal Abstinence Syndrome (DHM&NAS)
This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by Neolac Inc dba Medolac Laboratories
Sponsor:
Neolac Inc dba Medolac Laboratories
Collaborator:
University of Louisville
Information provided by (Responsible Party):
Neolac Inc dba Medolac Laboratories
ClinicalTrials.gov Identifier:
NCT02182973
First received: May 29, 2014
Last updated: July 2, 2014
Last verified: July 2014
https://clinicaltrials.gov/ct2/show/NCT02182973
Another contact has pointed out this connection between Medolac and the University of Louisville.
On Medolac's "leadership team":
"David Adamkin, MD is Medolac's Chief of Clinical and Medical Affairs and the Division Director of Neonatal Medicine at the University of Louisville as well as Professor of Pediatrics. He is also the Rounsavall Chair of Neonatology. He has published over 80 Peer reviewed publications, 40 book chapters and has written three books. Two of the books were for Polish Neonatology.
The majority of his research is related to neonatal nutrition. His research has centered on strategies to promote growth in Very Low Birth-weight Infants. He has participated in research related to preterm formula development, DHA/ARA additions to formula, development of human milk fortifiers and post discharge nutritional strategies. His early work related ti+o Total Parenteral Nutrition including development of amino acid formulations and avoiding complications with TPN. He has given over 300 scientific presentations nationally and internationally over the last few years. He also served on the Committee on the Fetus and Newborn of the American Academy of Pediatrics and was the author of the statement of Neonatal Hypoglycemia. He currently serves as the President of Southeastern Association of Neonatologists."
http://www.medolac.com/leadership.html
Post a Comment